Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 7Neoplasm Metastasis 5Colorectal Neoplasms 5Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumor 4Solid Tumor 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Esophageal Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Melanoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumour 2Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Metastatic Solid Tumors 1

Interventions

Fluorouracil 14pembrolizumab 13Paclitaxel 13Oxaliplatin 13Leucovorin 10Carboplatin 9Radiotherapy 8Capecitabine 8Trastuzumab 7Nivolumab 7Drug Therapy 7Cisplatin 7Radiation 6Esophagectomy 6Taxes 5Specimen Handling 5Irinotecan 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Immunotherapy 3Blood Specimen Collection 3zanidatamab 2ulixertinib 2trastuzumab biosimilar HLX02 2relatlimab 2durvalumab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Neoplasms × tislelizumab × 90 days × Clear all
NCT06914011 2026-06-02

MRD2START

Asan Medical Center

Phase 3 Not yet recruiting
172 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT06010303 2026-05-28

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

BeOne Medicines

Phase 2 Completed
118 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡